Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00384449 · ClinicalTrials.gov registry record · Phase 2
Lucentis (Ranibizumab) for Eales' Disease
A Phase 2 study of Eales' Disease, sponsored by Oregon Health and Science University.
- Completed
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
- 1
- Study location
NCT00384449 is a Phase 2 study of Eales' Disease that has completed, run by Oregon Health and Science University. The registered enrollment target is 1 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00384449, a Phase 2 study of Eales' Disease, has completed, sponsored by Oregon Health and Science University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective of this protocol is to look at whether Lucentis (ranibizumab) is safe and effective when used for macular edema (retinal swelling) due to Eales' disease. The secondary objective is to see if macular edema comes back within three months after the last dose of study drug is given.
Conditions Studied
Interventions
- DRUG Ranibizumab
Study Locations (1)
Oregon
- Casey Eye Institute - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2006-10 |
| Est. Completion | 2009-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00384449
The ClinicalTrials.gov registry entry for NCT00384449 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oregon Health and Science University, which has 546 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Eales' Disease appearing as the primary indexed condition, and to 1 intervention - of which Ranibizumab is the first listed.
NCT00384449 reports 1 study location spanning 1 distinct geographic area - top geographies include Oregon.
Frequently Asked Questions
What is clinical trial NCT00384449 about?
NCT00384449 is a clinical study titled "Lucentis (Ranibizumab) for Eales' Disease". The primary objective of this protocol is to look at whether Lucentis (ranibizumab) is safe and effective when used for macular edema (retinal swelling) due to Eales' disease. The secondary objective is to see if macular edema comes back within three months after the last dose of study drug is given...
What is the current status of trial NCT00384449?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2006-10. Estimated completion is 2009-04.
What conditions does trial NCT00384449 study?
This clinical trial studies the following conditions: Eales' Disease.
What interventions are being tested in trial NCT00384449?
The interventions under investigation include: Ranibizumab (DRUG).
Who is sponsoring clinical trial NCT00384449?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00384449 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.